163 related articles for article (PubMed ID: 38184121)
1. The determinants of metabolic discrepancies in aerobic glycolysis: Providing potential targets for breast cancer treatment.
Littleflower AB; Parambil ST; Antony GR; Subhadradevi L
Biochimie; 2024 May; 220():107-121. PubMed ID: 38184121
[TBL] [Abstract][Full Text] [Related]
2. Emerging roles of aerobic glycolysis in breast cancer.
Wu Z; Wu J; Zhao Q; Fu S; Jin J
Clin Transl Oncol; 2020 May; 22(5):631-646. PubMed ID: 31359335
[TBL] [Abstract][Full Text] [Related]
3. Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents.
Sheng H; Tang W
Recent Pat Anticancer Drug Discov; 2016; 11(3):297-308. PubMed ID: 27087655
[TBL] [Abstract][Full Text] [Related]
4. Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells.
Fukushi A; Kim HD; Chang YC; Kim CH
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077431
[TBL] [Abstract][Full Text] [Related]
5. Glycolysis-based drug delivery nanosystems for therapeutic use in tumors and applications.
Geng C; Pang S; Ye R; Shi J; Yang Q; Chen C; Wang W
Biomed Pharmacother; 2023 Sep; 165():115009. PubMed ID: 37343435
[TBL] [Abstract][Full Text] [Related]
6. Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis.
Arundhathi JRD; Mathur SR; Gogia A; Deo SVS; Mohapatra P; Prasad CP
Mol Biol Rep; 2021 May; 48(5):4733-4745. PubMed ID: 34047880
[TBL] [Abstract][Full Text] [Related]
7. Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells.
Motawi TM; Sadik NA; Fahim SA; Shouman SA
Chem Biol Interact; 2015 May; 233():147-56. PubMed ID: 25863232
[TBL] [Abstract][Full Text] [Related]
8. An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade.
Fortunato S; Bononi G; Granchi C; Minutolo F
ChemMedChem; 2018 Nov; 13(21):2251-2265. PubMed ID: 30226288
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide metabolite chloroacetaldehyde inhibits cell proliferation and glucose metabolism without decreasing cellular ATP content in human breast cancer cells MCF-7.
Knouzy B; Dubourg L; Baverel G; Michoudet C
J Appl Toxicol; 2010 Apr; 30(3):204-11. PubMed ID: 19774546
[TBL] [Abstract][Full Text] [Related]
10. Modeling cancer glycolysis under hypoglycemia, and the role played by the differential expression of glycolytic isoforms.
Marín-Hernández A; López-Ramírez SY; Del Mazo-Monsalvo I; Gallardo-Pérez JC; Rodríguez-Enríquez S; Moreno-Sánchez R; Saavedra E
FEBS J; 2014 Aug; 281(15):3325-45. PubMed ID: 24912776
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
12. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect.
Lu CL; Qin L; Liu HC; Candas D; Fan M; Li JJ
PLoS One; 2015; 10(3):e0121046. PubMed ID: 25807077
[TBL] [Abstract][Full Text] [Related]
13. Glycolysis inhibition for anticancer treatment.
Pelicano H; Martin DS; Xu RH; Huang P
Oncogene; 2006 Aug; 25(34):4633-46. PubMed ID: 16892078
[TBL] [Abstract][Full Text] [Related]
14. Targeting cellular metabolism to improve cancer therapeutics.
Zhao Y; Butler EB; Tan M
Cell Death Dis; 2013 Mar; 4(3):e532. PubMed ID: 23470539
[TBL] [Abstract][Full Text] [Related]
15. Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy.
Shi Y; Liu S; Ahmad S; Gao Q
Curr Top Med Chem; 2018; 18(6):454-466. PubMed ID: 29788889
[TBL] [Abstract][Full Text] [Related]
16. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase.
Marín-Hernández A; Rodríguez-Enríquez S; Vital-González PA; Flores-Rodríguez FL; Macías-Silva M; Sosa-Garrocho M; Moreno-Sánchez R
FEBS J; 2006 May; 273(9):1975-88. PubMed ID: 16640561
[TBL] [Abstract][Full Text] [Related]
17. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling.
Migneco G; Whitaker-Menezes D; Chiavarina B; Castello-Cros R; Pavlides S; Pestell RG; Fatatis A; Flomenberg N; Tsirigos A; Howell A; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Cell Cycle; 2010 Jun; 9(12):2412-22. PubMed ID: 20562527
[TBL] [Abstract][Full Text] [Related]
18. Targeting glucose metabolism to develop anticancer treatments and therapeutic patents.
Zhou Y; Guo Y; Tam KY
Expert Opin Ther Pat; 2022 Apr; 32(4):441-453. PubMed ID: 35001793
[TBL] [Abstract][Full Text] [Related]
19. Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation.
Marín-Hernández A; Gallardo-Pérez JC; López-Ramírez SY; García-García JD; Rodríguez-Zavala JS; Ruiz-Ramírez L; Gracia-Mora I; Zentella-Dehesa A; Sosa-Garrocho M; Macías-Silva M; Moreno-Sánchez R; Rodríguez-Enríquez S
Arch Toxicol; 2012 May; 86(5):753-66. PubMed ID: 22349057
[TBL] [Abstract][Full Text] [Related]
20. Contemporary Perspectives on the Warburg Effect Inhibition in Cancer Therapy.
Kozal K; Jóźwiak P; Krześlak A
Cancer Control; 2021; 28():10732748211041243. PubMed ID: 34554006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
